Centogene and Evotec Discover New molecule To Treat Gaucher Ailment

Centogene NV, the crucial life science partner for data-driven answers in rare and neurological illnesses, has announced the discovery of a new small molecule alongside Evotec SE. The novel chemical has the potential to help individuals with type 2 and type 3 Gaucher disease, also known as neuronopathic Gaucher disease. The finding was the product of joint work within the existing drug discovery partnership, which has been in place since 2020.

The firms have extended their relationship for another year, offering Evotec a research and development license for future development operations. The modified agreement also grants Evotec an exclusive option until March 31, 2025, to engage into a license deal to acquire Centogene's share of the IP created throughout the collaboration. Centogene would receive an upfront price, milestone payments, and extra royalties in exchange for this global exclusive license. Additional financial information was not given.

“This partnership is indicative of how we are able to successfully leverage our expansive know-how in rare diseases as well as the depth of the Centogene Biodatabank, which in combination with Evotec’s multi-modality platform has successfully identified drug candidates in Gaucher disease,” said Dr. Peter Bauer, chief medical and genomic officer at Centogene. “Importantly, together with Evotec, we have established a much deeper understanding of neuronopathic Gaucher disease than before, which we believe could accelerate the development of a new life-saving treatment for these patients worldwide.”

Centogene and Evotec have been collaborating since 2018 to investigate, find, and develop a chemical to lower the lysosomal molecule lyso-Gb1, which is significantly elevated in individuals with neuronopathic Gaucher disease.